(S)-(-)-3-(3-羟基苯基)-N-丙基哌啶 盐酸盐 | 88768-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (S)-(-)-3-(3-羟基苯基)-N-丙基哌啶 盐酸盐
• 中文别名: (S)-(-)-3-(3-羟基苯基)-N-丙基哌啶盐酸盐；丙克拉莫
• 英文名称: (-)-3-PPP hydrochloride
• 英文别名: (-)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine hydrochloride；S(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine hydrochloride；(+)-3-(3-hydroxyphenyl)-N-n-propylpiperidine hydrochloride；S(-)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride；preclamol hydrochloride；S(-)-3PPP hydrochloride；3-[(3S)-1-propylpiperidin-3-yl]phenol;hydrochloride
• CAS: 88768-67-6
• 化学式: C₁₄H₂₁NO*ClH
• 分子量: 255.788
• InChiKey: NRHUDETYKUBQJT-BTQNPOSSSA-N

物化性质

• 溶解度：
  在水中的溶解度150 mg/mL，溶液应现场配制。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  23.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 海关编码：
  2933399090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
: (S)-(−)-3-(3-Hydroxyphenyl)-N-propylpiperidine
Product name
hydrochloride
CAS-No. : 88768-67-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Preclamol
S-(−)-3-PPP
Formula : C14H21NO · HCl
Molecular Weight : 255,78 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

盐酸普瑞拉莫尔，化学名为(−)-3-聚丙烯盐酸盐，是一种选择性多巴胺自身受体激动剂。它在研究精神分裂症方面展现出潜在的价值。

反应信息

• 作为反应物：
  描述：

  (S)-(-)-3-(3-羟基苯基)-N-丙基哌啶 盐酸盐 在 rat liver microsome phosphate buffer 、 乙二胺四乙酸 、 还原型辅酶II(NADPH)四钠盐 、 magnesium chloride 、 维生素 C 作用下， 以 水 为溶剂， 生成 S(-)-3-(3,4-dihydroxyphenyl)-N-n-propylpiperidine hydrochloride
  参考文献：
  名称：

  In-vitro and in-vivo metabolism of the presynaptic dopamine agonist 3-PPP to a catecholic analogue in rats

  摘要：

  摘要：多巴胺激动剂3-PPP及其对映体在体外通过大鼠肝微粒体被羟化为儿茶酚胺3-(3,4-二羟基苯基)-N-正丙基哌啶(4-OH-3-PPP)，其Km和Vmax值分别约为1μM和2 nmol(mg蛋白质)−1 min−1。由于形成的儿茶酚胺似乎是儿茶酚-O-甲基转移酶的良好底物，因此在大鼠体内从3-PPP生成儿茶酚胺只有在用托普酮抑制COMT后才能检测到。在给予45 μmol kg−1 3-PPP i.p.或 s.c.注射后45分钟，通过高效液相色谱与电化学检测测量，产生的4-OH-3-PPP在脑中的水平约为i.p.注射后每克约350 pmol，s.c.注射后每克约100 pmol，对映体、(+)或(-) 3-PPP之间没有显著差异。估计这些儿茶酚胺水平在i.p.注射后约占3-PPP水平的1-5%，s.c.注射后约占3-PPP水平的0.2-0.5%。讨论了3-PPP的代谢转化对其药理特性的相关性。

  DOI：

  10.1111/j.2042-7158.1985.tb05073.x
• 作为产物：
  描述：

  丙克拉莫 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 (S)-(-)-3-(3-羟基苯基)-N-丙基哌啶 盐酸盐
  参考文献：
  名称：

  立体催化合成（-）-3-PPP通过钯催化的L-哌啉酸C-3位置的未活化C（sp 3）-H芳基化

  摘要：

  描述了使用高度立体选择性的钯催化的C（sp 3）-H芳基化和自由基脱羧反应作为关键步骤制备（-）-3-PPP（preclamol）的有效途径。在关键反应中形成的1-哌啉酸衍生物的C-3位的手性中心是由底物的相邻立体中心完全诱导的，这由手性HPLC分析的数据所证实。通过大量实验，包括钯络合物2的X射线单晶衍射分析，探索了氮对Pd催化的C（sp 3）-H芳基化反应效率的取代作用。

  DOI：

  10.1016/j.tetlet.2016.12.051

文献信息

• Dopamine analog amide
  申请人：——

  公开号：US20010056116A1

  公开（公告）日：2001-12-27

  The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

  该发明涉及使用脂肪酸载体和神经活性药物形成前药。该前药在胃和血液流动环境中稳定，并可通过口服递送。该前药容易穿过血脑屏障。一旦进入中枢神经系统，前药被水解成脂肪酸载体和药物以释放药物。在首选实施方式中，载体是4,7,10,13,16,19二十二碳六烯酸，药物是多巴胺。两者都是中枢神经系统的正常成分。药物和载体之间的共价键通常是酰胺键，这种键可以在胃的条件下存活。因此，前药可以被摄入，并且不会在胃中完全水解成载体分子和药物分子。
• METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION
  申请人：Quake Stephen R.

  公开号：US20100260717A1

  公开（公告）日：2010-10-14

  Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.
• US5994392A
  申请人：——

  公开号：US5994392A

  公开（公告）日：1999-11-30
• US6107499A
  申请人：——

  公开号：US6107499A

  公开（公告）日：2000-08-22
• US6258836B1
  申请人：——

  公开号：US6258836B1

  公开（公告）日：2001-07-10